Bioseeker, Feb 2011
of ceased drugs over the last years amount to another 28 (25) drugs. BladderCancerDrugPipelineUpdate lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked
Global Industry Analysts, Inc., Oct 2010, Pages: 580
BladderCancer Demands New Therapeutics to Fill the Void II-6
Table 5: Number of PipelineDrugs by Select Cancer Types
(includes corresponding Graph/Chart
Life Science Analytics, March 2011, Pages: 192
BladderCancer Therapy Area Pipeline Report contains detailed information on the bladdercancerdrugpipeline. This report provides insight into the pipeline status of bladdercancerdrugs
Global Markets Direct, Dec 2010, Pages: 114
BladderCancer - Pipeline Review, Q4 2010
Summary
Global Markets Direct’s, “BladderCancerPipeline Review, Q4 2010”, provides an overview of the BladderCancer therapeutic pipeline. This report
Global Markets Direct, Feb 2011, Pages: 116
BladderCancer - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'BladderCancer - Pipeline Review, Q1 2011', provides an overview of the BladderCancer therapeutic pipeline. This report
Bioseeker, Dec 2007, Pages: 430
Therapeutic Effects
9.1 Anti-Angiogenesis
9.2 Apoptosis
9.3 Protein Kinase Inhibitors
10 Antibody Targets and Drugs by Cancer Indications
10.1 Basal Cell Cancer
10.2 Biliary Cancer
10.3 BladderCancer
Bioseeker, Sep 2007, Pages: 500
Diagnosis
5.1.3 BladderCancer and Melanoma Registration Filings are Emminent
5.1.4 The Human Kinome and Cell Cycle Inhibitors
5.1.5 Strategic Priorities in Pipeline Development Leads to Divestments
5
GlobalData, Nov 2010, Pages: 36
Receives FDA Approval To Continue Phase IIb Superficial BladderCancer Clinical Trial
Aug 24, 2009: BioCancell Receives Orphan Drug Status From FDA For Ovarian CancerDrug
Jan 13, 2009: Bio
Global Markets Direct, Nov 2010, Pages: 36
” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant
Jain PharmaBiotech, Feb 2012, Pages: 659
Gene therapy of cancer of selected organs
Gene therapy for bladdercancer
Gene therapy for glioblastoma multiforme.
Adenoviral vectors for treatment of brain tumors
Antiangiogenic gene therapy
GlobalData, Nov 2010, Pages: 27
” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant
Global Markets Direct, Nov 2010, Pages: 27
” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant
GlobalData, Nov 2010, Pages: 73
on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report
Global Markets Direct, Nov 2010, Pages: 73
on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report
Global Markets Direct, Nov 2011, Pages: 132
” provides data on the Spectrum Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features
Global Markets Direct, Nov 2011, Pages: 103
on the Celldex Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant
Global Markets Direct, March 2011, Pages: 86
In Advanced Gastric Cancer Patients
Oct 11, 2010: Genta Receives European Orphan Drug Designation For Tesetaxel
Sep 24, 2010: Genta Initiates Phase II Trial Of Tesetaxel In Patients With Advanced Bladder
Global Markets Direct, Nov 2011, Pages: 36
Of VB6-845 Anti-Cancer Antibody
Oct 10, 2005: Viventia Biotech Provides Update Of Vicinium Clinical Program
Apr 03, 2007: Viventia Biotech Initiates Patient Treatment For Vicinium Phase II Bladder
GlobalData, Nov 2010, Pages: 85
In Advanced Gastric Cancer Patients
Oct 11, 2010: Genta Receives European Orphan Drug Designation For Tesetaxel
Sep 24, 2010: Genta Initiates Phase II Trial Of Tesetaxel In Patients With Advanced Bladder
